|
1.
|
Baselga J and Averbuch SD: ZD1839
(‘Iressa’) as an anticancer agent. Drugs. 60:33–40. 2000.
|
|
2.
|
Shepherd FA, Rodrigues Pereira J, Ciuleanu
T, et al: Erlotinib in previously treated non-small-cell lung
cancer. N Engl J Med. 2:123–132. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Kris MG, Natale RB, Herbst RS, et al:
Efficacy of gefitinib, an inhibitor of the epidermal growth factor
receptor tyrosine kinase, in symptomatic patients with non-small
cell lung cancer: a randomized trial. JAMA. 16:2149–2158. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Inoue A, Suzuki T, Fukuhara T, et al:
Prospective phase II study of gefitinib for chemotherapy-naive
patients with advanced non-small-cell lung cancer with epidermal
growth factor receptor gene mutations. J Clin Oncol. 21:3340–3346.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Yun CH, Mengwasser KE, Toms AV, et al: The
T790M mutation in EGFR kinase causes drug resistance by increasing
the affinity for ATP. Proc Natl Acad Sci USA. 6:2070–2075. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Engelman JA, Zejnullahu K, Mitsudomi T, et
al: MET amplification leads to gefitinib resistance in lung cancer
by activating ERBB3 signaling. Science. 5827:1039–1043. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Guha U, Chaerkady R, Marimuthu A, et al:
Comparisons of tyrosine phosphorylated proteins in cells expressing
lung cancer-specific alleles of EGFR and KRAS. Proc Natl Acad Sci
USA. 37:14112–14117. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Arthur WT and Burridge K: RhoA
inactivation by p190RhoGAP regulates cell spreading and migration
by promoting membrane protrusion and polarity. Mol Biol Cell.
9:2711–2720. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Tikoo A, Czekay S, Viars C, et al: p190-A,
a human tumor suppressor gene, maps to the chromosomal region
19q13.3 that is reportedly deleted in some gliomas. Gene. 1:23–31.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Roof RW, Haskell MD, Dukes BD, Sherman N,
Kinter M and Parsons SJ: Phosphotyrosine (p-Tyr)-dependent and
-independent mechanisms of p190 RhoGAP-p120 RasGAP interaction: Tyr
1105 of p190, a substrate for c-Src, is the sole p-Tyr mediator of
complex formation. Mol Cell Biol. 12:7052–7063. 1998.PubMed/NCBI
|
|
11.
|
Moran MF, Polakis P, McCormick F, Pawson T
and Ellis C: Protein-tyrosine kinases regulate the phosphorylation,
protein interactions, subcellular distribution and activity of
p21ras GTPase-activating protein. Mol Cell Biol. 4:1804–1812.
1991.
|
|
12.
|
Kusama T, Mukai M, Endo H, et al:
Inactivation of Rho GTPases by p190 RhoGAP reduces human pancreatic
cancer cell invasion and metastasis. Cancer Sci. 9:848–853. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Shen CH, Chen HY, Lin MS, et al: Breast
tumor kinase phosphorylates p190RhoGAP to regulate rho and ras and
promote breast carcinoma growth, migration and invasion. Cancer
Res. 19:7779–7787. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Moon SY and Zheng Y: Rho GTPase-activating
proteins in cell regulation. Trends Cell Biol. 1:13–22. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Costa DB, Halmos B, Kumar A, et al: BIM
mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung
cancers with oncogenic EGFR mutations. PLoS Med. 10:1669–1679.
2007.PubMed/NCBI
|
|
16.
|
Mitchell CE, Belinsky SA and Lechner JF:
Detection and quantitation of mutant K-ras codon 12 restriction
fragments by capillary electrophoresis. Anal Biochem. 1:148–153.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Forbes S, Clements J, Dawson E, et al:
Cosmic 2005. Br J Cancer. 2:318–322. 2006. View Article : Google Scholar
|
|
18.
|
Massarelli E, Varella-Garcia M, Tang X, et
al: KRAS mutation is an important predictor of resistance to
therapy with epidermal growth factor receptor tyrosine kinase
inhibitors in non-small-cell lung cancer. Clin Cancer Res.
10:2890–2896. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Detterbeck FC, Boffa DJ and Tanoue LT: The
new lung cancer staging system. Chest. 1:260–271. 2009. View Article : Google Scholar
|
|
20.
|
Ma L, Liu YP, Geng CZ, Wang XL, Wang YJ
and Zhang XH: Over expression of RhoA is associated with
progression in invasive breast duct carcinoma. Breast J. 1:105–107.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Xiaorong L, Wei W, Liyuan Q and Kaiyan Y:
Underexpression of deleted in liver cancer 2 (DLC2) is associated
with overexpression of RhoA and poor prognosis in hepatocellular
carcinoma. BMC Cancer. 8:2052008. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Dittert DD, Kielisch C, Alldinger I, et
al: Prognostic significance of immunohistochemical RhoA expression
on survival in pancreatic ductal adenocarcinoma: a high-throughput
analysis. Hum Pathol. 7:1002–1010. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Takenawa T and Miki H: WASP and WAVE
family proteins: key molecules for rapid rearrangement of cortical
actin filaments and cell movement. J Cell Sci. 10:1801–1809.
2001.PubMed/NCBI
|
|
24.
|
Tsubakimoto K, Matsumoto K, Abe H, et al:
Small GTPase RhoD suppresses cell migration and cytokinesis.
Oncogene. 15:2431–2440. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Downward J: Targeting RAS signalling
pathways in cancer therapy. Nat Rev Cancer. 1:11–22. 2003.
View Article : Google Scholar : PubMed/NCBI
|
